Compare State Street SPDR S&P Biotech ETF (XBI) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs State Street SPDR S&P Homebuilders ETF — how do they compare? State Street SPDR S&P Biotech ETF trades at $154.38, while State Street SPDR S&P Homebuilders ETF trades at $105.91. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| XBI | XHB | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $164.28 | $121.36 |
52-Week Low | $85.16 | $94.86 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
XHB trades at $106.07, down 2.01% over the past day amid a bearish technical signal. The ETF faces mixed housing data, with June home sales declining but new legislation potentially boosting homebuilding. Technical indicators show resistance near $108 and support at $105, while oscillators remain neutral. Recent news highlights affordability challenges from high mortgage rates and record prices, yet some sentiment improvement exists.
Outlook hinges on housing market dynamics and interest rate trends. Opportunities include potential gains from the new housing law, but risks involve persistent sales weakness and economic sensitivity. Investors should weigh legislative tailwinds against macroeconomic headwinds for directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
